




Patent Docket P1869R1

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

|   |   |
|---|---|
| In re Application of<br><br>Michelle Schaffer et al<br><br>Serial No.: 10/066,009<br><br>Filed: February 1, 2002<br><br>For: CRYSTALLIZATION OF IGF-1 | Group Art Unit: Unassigned<br><br>Examiner: Unassigned<br><br><b>CERTIFICATE OF MAILING</b><br>I hereby certify that this correspondence is being deposited with the United States Postal Service with sufficient postage as first class mail in an envelope addressed to: Assistant Commissioner of Patents, Washington, D.C. 20231 on<br><br>June 19, 2002<br><br><br>Emily Dutra |
|---|---|

#9  
Plunkett  
9/6/02

**INFORMATION DISCLOSURE STATEMENT**

Assistant Commissioner of Patents  
Washington, D.C. 20231

Sir:

Applicants submit herewith patents, publications or other information (attached hereto and listed on the attached revised Form PTO-1449) of which they are aware, which they believe may be material to the examination of this application and in respect of which there may be a duty to disclose in accordance with 37 CFR §1.56.

This Information Disclosure Statement is filed in accordance with the provisions of:

☒ **37 CFR §1.97(b)**

- within three months of the filing date of the application other than a continued prosecution application under 37 CFR §1.53(d); or
- within three months of the date of entry of the national stage of a PCT application as set forth in 37 CFR §1.491, or
- before the mailing of the first Office action on the merits; or
- before the mailing of the first Office action after the filing of a request for a continued examination under 37 CFR §1.114.

☐ **37 CFR §1.97(c)**

- by the applicant after the period specified in 37 CFR §1.97(b), but prior to the mailing date of any of a final action under 37 CFR §1.113, or a notice of allowance under 37 CFR §1.311, or an action that otherwise closes prosecution in the application, and is accompanied by either the fee set forth in 37 CFR §1.17(p) or a statement as specified in 37 CFR §1.97(e), as checked below.

☐ **37 CFR §1.97(d)**

- after the period specified in CFR §1.97(c), and is accompanied by the fee set forth in 37 CFR §1.17(p) and a statement as specified in 37 CFR §1.97(e), as checked below.

07/08/2002 14:00:00 00000062 070630 10066009  
01 FC:126 180.00 CH

[If either of boxes 37 CFR §1.97(c) or 37 CFR §1.97(d) is checked above, the following statement under 37 CFR §1.97(e) may need to be completed.]

- ☐ **37 CFR §1.97(e)** Each item of information contained in the information disclosure statement was first cited in any communication from a foreign patent office in a counterpart foreign application not more than three months prior to the filing of this information disclosure statement.
- ☐ **37 CFR §1.704(d)** Each item of information contained in the information disclosure statement was cited in a communication from a foreign patent office in a counterpart foreign application and the communication was not received by any individual designated in §1.56(c) more than thirty days prior to the filing of this information disclosure statement. Therefore, in accordance with the provisions of 37 CFR §1.704(d), the filing of this information disclosure statement will not be considered a failure to engage in reasonable efforts to conclude prosecution under 37 CFR §1.704.
- ☐ The U.S. Patent and Trademark Office is hereby authorized to charge Deposit Account No. 07-0630 in the amount of \$180.00 to cover the cost of this Information Disclosure Statement under 37 CFR §1.17(p). Any deficiency or overpayment should be charged or credited to this deposit account.

A list of the patent(s) or publication(s) is set forth on the attached revised Form PTO-1449 (Modified).

**A copy of the items on PTO-1449 is supplied herewith.**

Those patent(s) or publication(s) which are marked with an asterisk (\*) in the attached PTO-1449 form are not supplied.

☐ **BLAST results enclosed:**

The undersigned also wishes to bring to the attention of the Examiner BLAST results of computerized alignments of the against sequences contained in the nucleotide and protein databases. The BLAST results are provided in paper form and are identified as reference "BLAST Results A-1- A-())" (nucleotide) and "BLAST Results B-1 - B-())" (protein) on the PTO Form 1449. Applicant requests that these references also be considered and that the Form 1449 be initialed to indicate the Examiner's consideration of the references.

A concise explanation of relevance of the items listed on PTO-1449 is:

- ☐ not given
- ☐ given for each listed item
- ☒ given for only non-English language listed item(s) [Required]  
An English language abstract is attached to item 64.
- ☐ in the form of an English language copy of a Search Report from a foreign patent office, issued in a counterpart

Serial No.: 10/066,009  
Filed: February 1, 2002

Page 3

application, which refers to the relevant portions of the references.

In accordance with 37 CFR §1.97(g), the filing of this information disclosure statement shall not be construed as a representation that a search has been made.

In accordance with 37 CFR §1.97(h), the filing of this information disclosure statement shall not be construed to be an admission that the information cited in the statement is, or is considered to be, material to patentability as defined in 37 CFR § 1.56(b).

In the event that the Office determines a fee to be due where none is specifically authorized in this paper, the U.S. Patent and Trademark Office is hereby authorized to charge Deposit Account No. 07-0630 in the amount of \$180.00 to cover the cost of this Information Disclosure Statement under 37 CFR §1.17(p).

Respectfully submitted,

GENENTECH, INC.

Date: June 19, 2002

By: Janet E. Hasak  
Janet E. Hasak  
Reg. No. 28,616  
Telephone No. (650) 225-1896



09157

PATENT TRADEMARK OFFICE



FORM PTO-1449

U.S. Dept. of Commerce  
Patent and Trademark Office

Atty Docket No.

P1869R1

Serial No.

10/066,009

## LIST OF DISCLOSURES CITED BY APPLICANT

(Use several sheets if necessary)

Applicant

Schaffer, M. et al.

Filing Date

01 Feb 2002

Group

NOT KNOWN

## U.S. PATENT DOCUMENTS

| Examiner Initials |    | Document Number | Date     | Name                 | Class | Subclass | Filing Date |
|-------------------|----|-----------------|----------|----------------------|-------|----------|-------------|
|                   | 2  | 4,672,108       | 09.06.87 | Kung et al.          |       |          |             |
|                   | 3  | 4,833,233       | 23.05.89 | Carter               |       |          |             |
|                   | 4  | 4,876,242       | 24.10.89 | Applebaum, J. et al. |       |          |             |
|                   | 5  | 4,959,351       | 25.09.90 | Grau                 |       |          |             |
|                   | 6  | 4,988,675       | 29.01.91 | Froesch et al.       |       |          |             |
|                   | 7  | 5,028,587       | 02.07.91 | Dorschug et al.      |       |          |             |
|                   | 8  | 5,068,224       | 26.11.91 | Fryklund et al.      |       |          |             |
|                   | 9  | 5,077,276       | 31.12.91 | Ballard, F. et al.   |       |          |             |
|                   | 10 | 5,093,317       | 03.03.92 | Lewis et al.         |       |          |             |
|                   | 11 | 5,106,832       | 21.04.92 | Froesch et al.       |       |          |             |
|                   | 12 | 5,126,324       | 30.06.92 | Clark et al.         |       |          |             |
|                   | 13 | 5,164,370       | 17.11.92 | Ballard, F. et al.   |       |          |             |
|                   | 14 | 5,187,151       | 16.02.93 | Clark et al.         |       |          |             |
|                   | 15 | 5,202,119       | 13.04.93 | Clark et al.         |       |          |             |
|                   | 16 | 5,273,961       | 28.12.93 | Clark                |       |          |             |
|                   | 17 | 5,374,620       | 20.12.94 | Clark et al.         |       |          |             |
|                   | 18 | 5,461,031       | 24.10.95 | De Felippis          |       |          |             |
|                   | 19 | 5,466,670       | 14.11.95 | Dunger, D.B. et al.  |       |          |             |
|                   | 20 | 5,470,828       | 28.11.95 | Ballard et al.       |       |          |             |
|                   | 21 | 5,504,188       | 02.04.96 | Baker et al.         |       |          |             |
|                   | 22 | 5,534,488       | 09.07.96 | Hoffmann             |       |          |             |
|                   | 23 | 5,547,930       | 20.08.96 | Balschmidt           |       |          |             |
|                   | 24 | 5,569,648       | 29.10.96 | Lewis, M. et al.     |       |          |             |
|                   | 25 | 5,597,893       | 28.01.97 | Baker et al.         |       |          |             |
|                   | 26 | 5,650,486       | 22.07.97 | De Felippis          |       |          |             |
|                   | 27 | 5,714,460       | 03.02.98 | Gluckman et al.      |       |          |             |
|                   | 28 | 5,747,642       | 05.05.98 | De Felippis          |       |          |             |
|                   | 29 | 5,834,422       | 10.11.98 | Balschmidt           |       |          |             |
|                   | 30 | 5,840,680       | 24.11.98 | Balschmidt           |       |          |             |
|                   | 31 | 5,898,028       | 27.04.99 | Jensen et al.        |       |          |             |
|                   | 32 | 5,898,067       | 27.04.99 | Balschmidt et al.    |       |          |             |
|                   | 33 | 5,948,751       | 07.09.99 | Kimer et al.         |       |          |             |
|                   | 34 | 5,952,297       | 14.09.99 | De Felippis et al.   |       |          |             |
|                   | 35 | 6,127,334       | 03.10.00 | Kimer et al.         |       |          |             |

Examiner

Date Considered

\*Examiner: Initial if reference considered, whether or not citation is in conformance with MPEP 609; draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

FORM PTO-1449

U.S. Dept. of Commerce  
Patent and Trademark Office

Atty Docket No.

P1869R1

Serial No.

10/066,009

## LIST OF DISCLOSURES CITED BY APPLICANT

(Use several sheets if necessary)

Applicant

Schaffer, M. et al.

Filing Date

01 Feb 2002

Group

NOT KNOWN

## FOREIGN PATENT DOCUMENTS

| Examiner<br>Initials |    | Document Number | Date     | Country | Class | Subclass | Translation |    |
|----------------------|----|-----------------|----------|---------|-------|----------|-------------|----|
|                      |    |                 |          |         |       |          | Yes         | No |
|                      | 36 | 668,914         | 30.08.95 | EP      |       |          |             |    |
|                      | 37 | WO 00/23469     | 27.04.00 | PCT     |       |          |             |    |
|                      | 38 | WO 91/03253     | 21.03.91 | PCT     |       |          |             |    |
|                      | 39 | WO 92/11865     | 23.07.92 | PCT     |       |          |             |    |
|                      | 40 | WO 93/08826     | 13.05.93 | PCT     |       |          |             |    |
|                      | 41 | WO 93/23067     | 25.11.93 | PCT     |       |          |             |    |
|                      | 42 | WO 93/23071     | 25.11.93 | PCT     |       |          |             |    |
|                      | 43 | WO 93/25219     | 23.12.93 | PCT     |       |          |             |    |
|                      | 44 | WO 94/04569     | 03.03.94 | PCT     |       |          |             |    |
|                      | 45 | WO 94/16722     | 04.08.94 | PCT     |       |          |             |    |
|                      | 46 | WO 96/01124     | 18.01.96 | PCT     |       |          |             |    |
|                      | 47 | WO 96/33216     | 24.10.96 | PCT     |       |          |             |    |
|                      | 48 | WO 97/00895     | 09.01.97 | PCT     |       |          |             |    |
|                      | 49 | WO 98/45427     | 15.10.98 | PCT     |       |          |             |    |
|                      | 50 | WO 99/01476     | 14.01.99 | PCT     |       |          |             |    |
|                      | 51 | WO 99/38011     | 29.07.99 | PCT     |       |          |             |    |

## OTHER DISCLOSURES (Including Author, Title, Date, Pertinent Pages, etc.)

|  |    |   |
|--|----|---|
|  | 52 | Adams et al., "Structure of Rhombohedral 2 Zinc Insulin Crystals." <u>Nature</u> . 224:491-495 (Nov 1969)   |
|  | 53 | Bach and Rechler., "Insulin-Like Growth Factor Binding Proteins." <u>Diabetes Reviews</u> . 3(1):38-61 (1995)   |
|  | 54 | Baker et al., "Role of Insulin-Like Growth Factors in Embryonic and Postnatal Growth." <u>Cell</u> . 75:73-82 (Oct 1993)  |
|  | 55 | Ballard et al., "Does IGF-I Ever Act Through the Insulin Receptor?" <u>The Insulin-Like Growth Factors and Their Regulatory Proteins</u> , Baxter, eds., Amsterdam: Elsevier pps. 131-138 (1994)                        |
|  | 56 | Bar et al., "Tissue Localization of Perfused Endothelial Cell IGF Binding Protein is Markedly Altered by Association with IGF-I." <u>Endocrinology</u> . 127(6):3243-3245 (1990)  |
|  | 57 | Barinaga, M., "Neurotrophic Factors Enter the Clinic [News]." <u>Science</u> . 264:772-774 (1994)   |
|  | 58 | Baserga., "The Insulin-Like Growth Factor 1 Receptor: A Key to Tumor Growth?" <u>Cancer Research</u> 55:249-252 (Jan 1995)  |
|  | 59 | Baxter, "Physiological Roles of IGF Binding Proteins" <u>Modern Concepts of Insulin-like Growth Factors</u> , Spencer, eds., Elsevier, New York pps. 371-380 (1991)   |
|  | 60 | Baxter., "The Somatomedins: Insulin-Like Growth Factors." <u>Advances in Clinical Chemistry</u> . 25:49-115 (1986)  |
|  | 61 | Bayne et al., "Structural Analogs of Human Insulin-Like Growth Factor I with Reduced Affinity for Serum Binding Proteins and the Type 2 Insulin-Like Growth Factor Receptor." <u>J. Bio. Chem.</u> 263:6233-6239 (1988) |

Examiner

Date Considered

\*Examiner: Initial if reference considered, whether or not citation is in conformance with MPEP 609; draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.



FORM PTO-1449

U.S. Dept. of Commerce  
Patent and Trademark OfficeAtty Docket No.  
P1869R1Serial No.  
10/066,009

## LIST OF DISCLOSURES CITED BY APPLICANT

(Use several sheets if necessary)

Applicant  
Schaffer, M. et al.Filing Date  
01 Feb 2002Group  
NOT KNOWN

## OTHER DISCLOSURES (Including Author, Title, Date, Pertinent Pages, etc.)

- |      |  |
|------|--|
| 62   | Bayne et al., "The C Region of Human Insulin-Like Growth Factor (IGF) I is Required for High Affinity Binding to the Type 1 IGF Receptor." <u>J. Bio. Chem.</u> 264(19):11004-11008 (1988)   |
| 63   | Bayne et al., "The Roles of Tyrosines 24, 31, and 60 in the High Affinity Binding of Insulin-Like Growth Factor-I to the Type I Insulin-Like Growth Factor Receptor." <u>J. Bio. Chem.</u> 265(26):15648-15652 (Sep 15, 1990)                            |
| 64   | Binoux, M., "Recent Data on Somatomedins (Insulin-Like Growth Factors)." <u>Annales d'Endocrinologie</u> (English Abstract Included) 41:157-192 (1980)   |
| 65   | Blundell et al., "Insulin-Like Growth Factor: A Model for Tertiary Structure Accounting for Immunoreactivity and Receptor Binding." <u>Proc. Natl. Acad. Sci. USA</u> 75(1):180-184 (Jan 1978)   |
| 66   | Blundell et al., "Tertiary Structures, Receptor Binding, and Antigenicity of Insulinlike Growth Factors." <u>Federation Proc.</u> 42:2592-2597 (1983)  |
| 67   | Bondy, C., "Clinical Uses of Insulin-Like Growth Factor I." <u>Annals of Internal Medicine.</u> 120:593-601 (1994)   |
| 68   | Buckbinder et al., "Induction of the Growth Inhibitor IGF-Binding Protein 3 by p53." <u>Nature.</u> 377:646-649 (Oct 1995)   |
| 69   | Cascieri et al., "Mutants of Human Insulin-Like Growth Factor I with Reduced Affinity for the Type 1 Insulin-Like Growth Factor Receptor." <u>Biochemistry</u> 27(9):3229-3233 (May 3, 1988)   |
| 70   | Cascieri et al., "Structural Analogs of Human Insulin-Like Growth Factor (IGF) I with Altered Affinity for Type 2 IGF Receptors." <u>J. Bio. Chem.</u> 264:2199-2202 (1989)  |
| * 71 | Cavanagh et al. <u>Protein NMR Spectroscopy: Principles and Practice.</u> , New York:Academic Press, Inc. (1996)   |
| 72   | Clemmons and Van Wyk., "Somatomedin: Physiological Control and Effects on Cell Proliferation." <u>Handbook Exp. Pharmacol.</u> 57:161-208 (1981)   |
| 73   | Clemmons et al., "Competition for Binding to Insulin-Like Growth Factor (IGF) Binding Protein-2, 3, 4, and 5 by the IGFs and IGF Analogs." <u>Endocrinology.</u> 131(2):890-895 (Aug 1992)   |
| 74   | Clemmons et al., "Discrete Alterations of the Insulin-Like Growth Factor I Molecule Which Alter Its Affinity for Insulin-Like Growth Factor-Binding Proteins Result in Changes in Bioactivity." <u>J. Bio. Chem.</u> 265(21):12210-12216 (1990)          |
| 75   | Clemmons et al., "The Role of Insulin-Like Growth Factors in the Nervous System." <u>Anal. NY Acad. Sci. USA</u> 692:10-21 (1993)  |
| 76   | Clore et al., "Stereospecific Assignment of $\beta$ -Methylene Protons in Larger Proteins Using 3D $^{15}\text{N}$ -Separated Hartmann-Hahn and $^{13}\text{C}$ -Separated Rotating Frame Overhauser Spectroscopy." <u>J. Biomol. NMR</u> 1:13-22 (1991) |
| 77   | Cohen et al., "Biological Effects of Prostate Specific Antigen as an Insulin-Like Growth Factor Binding Protein-3 Protease." <u>J. Endocrinology.</u> 142:407-415 (1994)   |
| 78   | Cohen et al., "Insulin-Like Growth Factors (IGFs), IGF Receptors, and IGF-Binding Proteins in Primary Cultures of Prostate Epithelial Cells." <u>J. Clin. Endocrin. &amp; Metab.</u> 73:401-407 (1991)   |
| 79   | Cohen et al., "The IGF Axis in the Prostate." <u>Horm. &amp; Metab. Res.</u> 26:81-84 (1994)   |
| 80   | Cooke et al., "Solution Structure of Human Insulin-Like Growth Factor 1: A Nuclear Magnetic Resonance and Restrained Molecular Dynamics Study" <u>Biochemistry</u> 30:5484-5491 (1991)   |
| 81   | Cornilescu et al., "Protein Backbone Angle Restraints From Searching a Database for Chemical Shift and Sequence Homology." <u>J. Biomol. NMR</u> 13:289-302 (1999)   |

Examiner

Date Considered

\*Examiner: Initial if reference considered, whether or not citation is in conformance with MPEP 609; draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.



FORM PTO-1449

U.S. Dept. of Commerce  
Patent and Trademark Office

Atty Docket No.

P1869R1

Serial No.

10/066,009

## LIST OF DISCLOSURES CITED BY APPLICANT

(Use several sheets if necessary)

Applicant

Schaffer, M. et al.

Filing Date

01 Feb 2002

Group

NOT KNOWN

## OTHER DISCLOSURES (Including Author, Title, Date, Pertinent Pages, etc.)

- |     |  |
|-----|--|
| 82  | Culig et al., "Androgen Receptor Activation in Prostatic Tumor Cell Lines by Insulin-Like Growth Factor-I, Keratinocyte Growth Factor, and Epidermal Growth Factor." <u>Cancer Research</u> . 54:5474-5478 (1994)  |
| 83  | Cullen et al., "Insulin-Like Growth Factor Receptor Expression and Function in Human Breast Cancer." <u>Cancer Research</u> . 50:48-53 (1990)  |
| 84  | Daughaday and Rotwein., "Insulin-Like Growth Factors I and II. Peptide, Messenger Ribonucleic Acid and Gene Structures, Serum, and Tissue Concentrations." <u>Endocrin. Rev.</u> 10(1):68-91 (1989)  |
| 85  | De Meyts., "The Structural Basis of Insulin and Insulin-Like Growth Factor-I Receptor Binding and Negative Co-Operativity, and its Relevance to Mitogenic Versus Metabolic Signalling." <u>Diabetologia</u> . (Suppl. 2) 37:S135-S148 (1994)                                 |
| 86  | De Wolf et al., "Solution Structure of a Mini IGF-1." <u>Protein Sci.</u> 5:2193-2202 (1996)   |
| 87  | Derewenda et al., "Phenol Stabilizes More Helix in a New Symmetrical Zinc Insulin Hexamer." <u>Nature</u> . 338:594-596 (Apr 1989)   |
| 88  | Dubaquie and Lowman, "Total Alanine-Scanning Mutagenesis of Insulin-Like Growth Factor I (IGF-I) Identifies Differential Binding Epitopes for IGFBP-1 and IGFBP-3." <u>Biochemistry</u> 38(20):6386-6396 (1999)  |
| 89  | Dubaquie et al., "Binding Protein-3-Selective Insulin-Like Growth Factor I Variants: Engineering, Biodistributions, and Clearance." <u>Endocrinology</u> . 142(1):165-173 (Jan 2001)   |
| 90  | Duerr et al., "Insulin-Like Growth Factor-1 Enhances Ventricular Hypertrophy and Function During the Onset of Experimental Cardiac Failure." <u>J. Clin. Invest.</u> 95:619-627 (1995)   |
| 91  | Einstein and Low., "Insulin: Some Shrinkage Stages of Sulfate and Citrate Crystals." <u>Acta Crystallogr.</u> 15:32-34 (1962)  |
| 92  | Elahi et al., "Hemodynamic and Metabolic Responses to Human Insulin-Like Growth Factor I (IGF-I) in Men." <u>Modern Concepts of Insulin-Like Growth Factors</u> , Spencer, EM, ed., New York:Elsevier Science Publ. Co. pps. 219-224 (1991)                                  |
| 93  | Fejzo et al., "The SHAPES Strategy: An NMR-Based Approach for Lead Generation in Drug Discovery." <u>Chemistry &amp; Biology</u> . 6:755-769 (1999)  |
| 94  | Feyen et al., "Recombinant Human [Cys <sup>281</sup> ]Insulin-Like Growth Factor-Binding Protein 2 Inhibits Both Basal and Insulin-Like Growth Factor I-Stimulated Proliferation and Collagen Synthesis in Fetal Rat Calvariae." <u>J. Bio. Chem.</u> 266:19469-19474 (1991) |
| 95  | Figuerola et al., "Recombinant Insulin-Like Growth Factor Binding Protein-1 Inhibits IGF-I, Serum, and Estrogen-Dependent Growth of MCF-7 Human Breast Cancer Cells." <u>J. Cell Phys.</u> 157:229-236 (1993)  |
| 96  | Froesch et al., "Metabolic and Therapeutic Effects of Insulin-Like Growth Factor I" <u>Horm. Res.</u> 42:66-71 (1994)  |
| 97  | Garrett et al., "Crystal Structure of the First Three Domains of the Type-1 Insulin-Like Growth Factor Receptor." <u>Nature</u> . 394(6691):395-399 (Jul 23, 1998)   |
| 98  | Guler et al., "Recombinant Human Insulin-Like Growth Factor 1 Stimulates Growth and has Distinct Effects on Organ Size in Hypophysectomized Rats." <u>Proc. Natl. Acad. Sci. USA</u> 85:4889-4893 (1988)   |
| 99  | Hammerman and Miller., "The Growth Hormone Insulin-Like Factor Axis in Kidney Revisited." <u>Am. J. Physiol.</u> 265:F1-F14 (1993)   |
| 100 | Hammerman and Miller., "Therapeutic Use of Growth Factors in Renal Failure." <u>J. Am. Soc. Nephrol.</u> 5:1-11 (1994)   |
| 101 | Hasegawa et al., "The Free Form of Insulin-Like Growth Factor I Increases in Circulation During Normal Human Pregnancy." <u>J. Clin. Endocrinol. Metabol.</u> 80:3284-3286 (1995)  |

Examiner

Date Considered

\*Examiner: Initial if reference considered, whether or not citation is in conformance with MPEP 609; draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

FORM PTO-1449

U.S. Dept. of Commerce  
Patent and Trademark Office

Atty Docket No.

P1869R1

Serial No.

10/066,009

## LIST OF DISCLOSURES CITED BY APPLICANT

(Use several sheets if necessary)

Applicant

Schaffer, M. et al.

Filing Date

01 Feb 2002

Group

NOT KNOWN

## OTHER DISCLOSURES (Including Author, Title, Date, Pertinent Pages, etc.)

|     |  |
|-----|--|
| 102 | Hizuka et al., "Measurement of Free Form of Insulin-Like Growth Factor I in Human Plasma." <u>Growth Regulation</u> . 1:51-55 (1991)   |
| 103 | Horney et al., "Elevated Glucose Increases Mesangial Cell Sensitivity to Insulin-Like Growth Factor I." <u>Am. J. Physiol.</u> 274:F1045-F1053 (1998)  |
| 104 | Hsing et al., "Regulation of Apoptosis Induced by Transforming Growth Factor- $\beta$ 1 in Nontumorigenic and Tumorigenic Rat Prostatic Epithelial Cell Lines." <u>Cancer Research</u> . 56:5146-5149 (1996)   |
| 105 | Humbel., "Insulin-Like Growth Factors I and II." <u>European Journal of Biochemistry</u> . 190:445-462 (1990)  |
| 106 | Huynh et al., "Estradiol and Antiestrogens Regulate a Growth Inhibitory Insulin-Like Growth Factor Binding Protein 3 Autocrine Loop in Human Breast Cancer Cells." <u>J. Bio. Chem.</u> 271(2):1016-1021 (1996)  |
| 107 | Isaksson et al., "Growth Hormone Stimulates Longitudinal Bone Growth Directly." <u>Science</u> . 216:1237-1239 (1982)  |
| 108 | Isaksson et al., "Mechanism of the Stimulatory Effect of Growth Hormone on Longitudinal Bone Growth." <u>Endocrine Reviews</u> . 8(4):426-438 (1987)   |
| 109 | Iwamura et al., "Insulin-Like Growth Factor I: Action and Receptor Characterization in Human Prostate Cancer Cell Lines." <u>Prostate</u> . 22:243-252 (1993)  |
| 110 | Jabri et al., "Adverse Effects of Recombinant Human Insulin-Like Growth Factor I in Obese Insulin-Resistant Type II Diabetic Patients." <u>Diabetes</u> 43:369-374 (1994)  |
| 111 | Janin and Chothia., "The Structure of Protein-Protein Recognition Sites." <u>J. Bio. Chem.</u> 265(27):16027-16030 (1990)  |
| 112 | Jansson et al., "The Insulin-Like Growth Factor (IGF) Binding Protein 1 Binding Epitope on IGF-I Probed by Heteronuclear NMR Spectroscopy and Mutational Analysis." <u>J. Bio. Chem.</u> 273(38):24701-24707 (September 18, 1998)  |
| 113 | Jones and Clemmons., "Insulin-Like Growth Factors and Their Binding Proteins: Biological Actions." <u>Endocrine Rev.</u> 16(1):3-34 (1995)   |
| 114 | Juul et al., "Serum Concentrations of Free and Total Insulin-Like Growth Factor-I, IGF Binding Proteins -1 and -3 and IGFBP-3 Protease Activity in Boys with Normal or Precocious Puberty." <u>Clin. Endocrin.</u> 44:515-523 (1996)   |
| 115 | Juul et al., "Serum Insulin-Like Growth Factor-I in 1030 Healthy Children, Adolescents, and Adults: Relation to Age, Sex, Stage of Puberty, Testicular Size, and Body Mass Index." <u>J. Clin. Endocrin. &amp; Metab.</u> 78(8):744-752 (1994)   |
| 116 | Juul et al., "Serum Levels of Insulin-Like Growth Factor (IGF)-Binding Protein-3 (IGFBP-3) in Healthy Infants, Children, and Adolescents: The Relation to IGF-I, IGF-II, IGFBP-1, IGFBP-2, Age, Sex, Body Mass Index, and Pubertal Maturation." <u>J. Clin. Endocrin. &amp; Metab.</u> 80:2534-2542 (1995) |
| 117 | Kerr et al., "Effect of Insulin-like Growth Factor-1 on the Responses to and Recognition of Hypoglycemia in Humans: A Comparison with Insulin." <u>J. Clin. Invest.</u> 91:141-147 (1993)  |
| 118 | Kuzuya et al., "Trial of Insulinlike Growth Factor I Therapy for Patients with Extreme Insulin Resistance Syndromes." <u>Diabetes</u> . 42:696-705 (1993)  |
| 119 | Laajoki et al., "Secondary Structure Determination of $^{15}\text{N}$ -Labelled Human Long-[Arg-3]-Insulin-Like Growth Factor 1 by Multidimensional NMR Spectroscopy." <u>FEBS Letters</u> 420:97-102 (1997)   |
| 120 | Laajoki et al., "Solution Structure and Backbone Dynamics of Long-[Arg <sup>3</sup> ]Insulin-Like Growth Factor-I." <u>J. Bio. Chem.</u> 275(14):10009-10015 (2000)  |
| 121 | Lee et al., "A Pulsed Field Gradient Isotope-Filtered 3D $^{13}\text{C}$ HMQC-NOESY Experiment for Extracting Intermolecular NOE Contacts in Molecular Complexes." <u>FEBS Letters</u> 350:87-90 (1994)  |

Examiner

Date Considered

\*Examiner: Initial if reference considered, whether or not citation is in conformance with MPEP 609; draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.



FORM PTO-1449

U.S. Dept. of Commerce  
Patent and Trademark Office

Atty Docket No.

P1869R1

Serial No.

10/066,009

## LIST OF DISCLOSURES CITED BY APPLICANT

(Use several sheets if necessary)

Applicant

Schaffer, M. et al.

Filing Date

01 Feb 2002

Group

NOT KNOWN

## OTHER DISCLOSURES (Including Author, Title, Date, Pertinent Pages, etc.)

- |      |  |
|------|--|
| 122  | Lee et al., "Activation of Estrogen Receptor-Mediated Gene Transcription by IGF-I in Human Breast Cancer Cells." <u>J. Endocrinol.</u> 152:39-47 (1997)  |
| 123  | Lee et al., "Regulation and Function of Insulin-Like Growth Factor-Binding Protein-1." <u>Proc. Soc. Exp. Biol. &amp; Med.</u> 204:4-29 (1993)   |
| 124  | LeRoith et al., "Insulin-Like Growth Factors and Cancer." <u>Annals of Internal Medicine.</u> 122(1):54-59 (Jan 1995)  |
| 125  | LeRoith., "Editorial: Insulin-Like Growth Factor I Receptor Signaling-- Overlapping or Redundant Pathways?" <u>Endocrinology.</u> 141(4):1287-1288 (2000)  |
| 126  | Lewitt and Baxter, "Insulin-Like Growth Factor-Binding Protein-1: A Role in Glucose Counterregulation?" <u>Mol. Cell. Endocrin.</u> 79(1-3):C147-C152 (1991)   |
| 127  | Lewitt et al., "Insulin-like Growth Factor-binding Protein-1 Modulates Blood Glucose Levels" <u>Endocrinology</u> 129(4):2254-2256 (1991)  |
| 128  | Lieberman et al., "Effects of Recombinant Human Insulin-Like Growth Factor-I (rhIGF-I) on Total and Free IGF-I Concentrations, IGF-Binding Proteins, and Glycemic Response in Humans." <u>J. Clin. Endocrinol. &amp; Metab.</u> 75(1):30-36 (1992)   |
| 129  | Liu et al., "Insulin-Like Growth Factor-I Affects Perinatal Lethality and Postnatal Development in a Gene Dosage-Dependent Manner: Manipulation Using the Cre/loxP System in Transgenic Mice." <u>Molecular Endocrinology</u> 12(9):1452-1462 (1998) |
| 130  | Liu et al., "Mice Carrying Null Mutations of the Genes Encoding Insulin-Like Growth Factor I (Igf-1) and Type I IGF Receptor (Igf1r)." <u>Cell.</u> 75:59-72 (Oct 1993)  |
| 131  | Long et al., "Loss of the Metastatic Phenotype in Murine Carcinoma Cells Expressing an Antisense RNA to the Insulin-Like Growth Factor Receptor." <u>Cancer Research.</u> 55:1006-1009 (1995)  |
| 132  | Lowman et al., "Molecular Mimics of Insulin-Like Growth Factor 1 (IGF-1) for Inhibiting IGF-1: IGF-Binding Protein Interactions." <u>Biochemistry</u> 37(25):8870-8878 (1998)  |
| 133  | McGuire et al., "Regulation of Insulin-Like Growth Factor-Binding Protein (IGFBP) Expression by Breast Cancer Cells: Use of IGFBP-1 as an Inhibitor of Insulin-Like Growth Factor Action." <u>J. Natl. Cancer Institute</u> 84(17):1336-1341 (1992)  |
| *134 | McPherson, Alexander. <u>Preparation and Analysis of Protein Crystals.</u> (Second Edition), Malabar, FL:Robert E. Krieger Publishing Comp. (1989)   |
| 135  | Morrow et al., "Recombinant Human (rh) IGF-1 Reverses Hyperglycemia and Improves Insulin Sensitivity in Severe Insulin Resistance" <u>Diabetes-53rd Annual Meeting, June 12-15, 1993</u> (Suppl. 1, abstract No. 269) 42:83A (1993)                  |
| 136  | Oh et al., "Antiproliferative Actions of Insulin-Like Growth Factor Binding Protein (IGFBP)-3 in Human Breast Cancer Cells." <u>Prog. Growth Factor Res.</u> 6(2-4):503-512 (1995)   |
| 137  | Oh et al., "Characterization of the Affinities of Insulin-Like Growth Factor (IGF)-Binding Proteins 1-4 for IGF-I, IGF-II, IGF-I/Insulin Hybrid, and IGF-I Analogs." <u>Endocrinology.</u> 132:1337-1344 (1993)                                      |
| 138  | Oh et al., "Insulin-Like Growth Factor (IGF)-Independent Action of IGF-Binding Protein-3 in Hs578T Human Breast Cancer Cells." <u>J. Bio. Chem.</u> 268(20):14964-14971 (1993)   |
| 139  | Peterkofsky et al., "Elevated Activity of Low Molecular Weight Insulin-Like Growth Factor-Binding Proteins in Sera of Vitamin C-Deficient and Fasted Guinea Pigs" <u>Endocrinology</u> 128(4):1769-1779 (1991)                                       |
| 140  | Pietrzkowski et al., "Inhibition of Cellular Proliferation by Peptide Analogues of Insulin-Like Growth Factor 1." <u>Cancer Research.</u> 52:6447-6451 (1992)  |
| 141  | Powell-Braxton et al., "IGF-I is Required for Normal Embryonic Growth in Mice." <u>Genes Dev.</u> 7:2609-2617 (1993)   |

Examiner

Date Considered

\*Examiner: Initial if reference considered, whether or not citation is in conformance with MPEP 609; draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

FORM PTO-1449

U.S. Dept. of Commerce  
Patent and Trademark Office

Atty Docket No.

P1869R1

Serial No.

10/066,009

## LIST OF DISCLOSURES CITED BY APPLICANT

(Use several sheets if necessary)

Applicant

Schaffer, M. et al.

Filing Date

01 Feb 2002

Group

NOT KNOWN

## OTHER DISCLOSURES (Including Author, Title, Date, Pertinent Pages, etc.)

- |     |   |
|-----|---|
| 142 | Pratt and Pollak., "Insulin-Like Growth Factor Binding Protein 3 (IGF-BP3) Inhibits Estrogen-Stimulated Breast Cancer Cell Proliferation." <u>Biophys. Res. Comm.</u> 198(1):292-297 (1994)   |
| 143 | Quin et al., "Acute Response to Recombinant Insulin-Like Growth Factor I in a Patient with Mendenhall's Syndrome." <u>New Engl. J. Med.</u> 323(20):1425-1426 (1990)  |
| 144 | Quinn et al., "Insulin-Like Growth Factor Expression in Human Cancer Cell Lines." <u>J. Bio. Chem.</u> 271(19):11477-11483 (1996)   |
| 145 | Rajah et al., "Insulin-Like Growth Factor (IGF)-Binding Protein-3 Induces Apoptosis and Mediates the Effects of Transforming Growth Factor- $\beta$ 1 on Programmed Cell Death through a p53- and IGF-Independent Mechanism." <u>J. Bio. Chem.</u> 272(18):12181-12188 (1997)     |
| 146 | Reilly and Fairbrother., "A Novel Isotope Labeling Protocol for Bacterially Expressed Proteins." <u>J. Biomol. NMR</u> 4:459-462 (1994)   |
| 147 | Rinderknecht and Humbel, "Amino-Terminal Sequences of Two Polypeptides From Human Serum with Nonsuppressible Insulin-Like and Cell-Growth-Promoting Activities: Evidence for Structural Homology with Insulin B Chain." <u>Proc. Natl. Acad. Sci. USA</u> 73(12):4379-4381 (1976) |
| 148 | Rinderknecht and Humbel., "The Amino Acid Sequence of Human Insulin-Like Growth Factor I and Its Structural Homology with Proinsulin." <u>Journal of Biological Chemistry</u> 253(8):2769-2776 (1978)   |
| 149 | Rohlik et al., "An Antibody to the Receptor for Insulin-Like Growth Factor I Inhibits the Growth of MCF-7 Cells in Tissue Culture." <u>Biochem. &amp; Biophys. Res. Comm.</u> 149(1):276-281 (Nov 1987)   |
| 150 | Saad et al., "Low-Doses of Insulin-Like Growth Factor-I Improve Insulin Sensitivity." <u>Diabetologia</u> . (Abstract 152) 37:A40 (Supp. 1 1994)  |
| 151 | Sato et al., "Three-Dimensional Structure of Human Insulin-Like Growth Factor-I (IGF-I) Determined by $^1\text{H}$ -NMR and Distance Geometry." <u>Int. J. Pep. Protein Res.</u> 41:433-440 (1993)  |
| 152 | Schalch et al., "Short-Term Effects of Recombinant Human Insulin-Like Growth Factor I on Metabolic Control of Patients with Type II Diabetes Mellitus" <u>J. of Clinical Endocrinology &amp; Metabolism</u> 77(6):1563-1568 (1993)  |
| 153 | Schalch et al., "Short-Term Metabolic Effects of Recombinant Human Insulin-Like Growth Factor I (rhIGF-I) in Type II Diabetes Mellitus." <u>Modern Concepts of Insulin-Like Growth Factors</u> , Spencer, ed., New York:Elsevier Science Publ. Co. pps. 705-713 (1991)            |
| 154 | Schlechter et al., "Evidence Suggesting that the Direct Growth-Promoting Effect of Growth Hormone on Cartilage In Vivo is Mediated by Local Production of Somatomedin." <u>Proc. Natl. Acad. Sci. USA</u> 83:7932-7934 (1986)   |
| 155 | Schoenle et al., "Recombinant Human Insulin-Like Growth Factor I (rhIGF I) Reduces Hyperglycaemia in Patients with Extreme Insulin Resistance." <u>Diabetologia</u> . 34:675-679 (1991)   |
| 156 | Sjogren et al., "Liver-Derived Insulin-Like Growth Factor I (IGF-I) is the Principal Source of IGF-I in Blood but is Not Required for Postnatal Body Growth in Mice." <u>Proc. Natl. Acad. Sci. USA</u> 96:7088-7092 (1999)   |
| 157 | Smith et al., "Essential Role of Growth Hormone in Ischemia-Induced Retinal Neovascularization." <u>Science</u> . 276:1706-1709 (1997)  |
| 158 | Steller et al., "Overexpression of the Insulin-Like Growth Factor-1 Receptor and Autocrine Stimulation in Human Cervical Cancer Cells." <u>Cancer Research</u> . 56:1761-1765 (1996)  |
| 159 | Stracke et al., "The Type I Insulin-Like Growth Factor Receptor is a Motility Receptor in Human Melanoma Cells." <u>J. Bio. Chem.</u> 264(36):21544-21549 (Dec 1989)  |
| 160 | Sulkari et al., "Insulin Regulates the Serum Levels of Low Molecular Weight Insulin-Like Growth Factor-Binding Protein." <u>J. Clin. Endocrin. Metabol.</u> 66:266-272 (1988)   |
| 161 | Tollefsen and Thompson., "The Structural Basis for Insulin-Like Growth Factor I Receptor High Affinity Binding." <u>J. Bio. Chem.</u> 263(31):16267-16273 (1988)  |

Examiner

Date Considered

\*Examiner: Initial if reference considered, whether or not citation is in conformance with MPEP 609; draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

FORM PTO-1449

U.S. Dept. of Commerce  
Patent and Trademark Office

Atty Docket No.

P1869R1

Serial No.

10/066,009

## LIST OF DISCLOSURES CITED BY APPLICANT

(Use several sheets if necessary)

Applicant

Schaffer, M. et al.

Filing Date

01 Feb 2002

Group

NOT KNOWN

## OTHER DISCLOSURES (Including Author, Title, Date, Pertinent Pages, etc.)

- |     |   |
|-----|---|
| 162 | Torres et al., "Solution Structure of Human Insulin-Like Growth Factor II: Relationship to Receptor and Binding Protein Interactions." <u>J. Mol. Bio.</u> 248(2):385-401 (Apr 28, 1995)                                      |
| 163 | Usala et al., "Brief Report: Treatment of Insulin-Resistant Diabetic Ketoacidosis with Insulin-Like Growth Factor I in an Adolescent with Insulin-Dependent Diabetes." <u>New Engl. J. Med.</u> 327(12):853-857 (1992)        |
| 164 | Vajdos et al., "Crystal Structure of Human Insulin-Like Growth Factor-1: Detergent Binding Inhibits Binding Protein Interactions." <u>Biochemistry</u> 40:11022-11029 (2001)  |
| 165 | Valentinis et al., "The Human Insulin-Like Growth Factor (IGF) Binding Protein-3 Inhibits the Growth of Fibroblasts with a Targeted Disruption of the IGF-I Receptor Gene." <u>Molecular Endocrinology</u> . 9:361-367 (1995) |
| 166 | Van Holde., "X-Ray Diffraction." <u>Physical Biochemistry</u> , NJ:Prentice Hall, Chapter 11, pps. 221-239 (1971)   |
| 167 | Van Wyk et al., "The Somatomedins: A Family of Insulinlike Hormones Under Growth Hormone Control." <u>Recent Prog. Horm. Res.</u> 30:259-318 (1974)   |
| 168 | Vlachopapadopoulou et al., "Metabolic and Clinical Response to Recombinant Human Insulin-like Growth Factor I in Myotonic Dystrophy - A Clinical Research Center Study" <u>J. Clin. Endo. Metab.</u> 80(12):3715-3723 (1995)  |
| 169 | Weber., "Physical Principles of Protein Crystallization." <u>Advances in Protein Chemistry</u> . 41:1-36 (1991)   |
| 170 | Yee et al., "Insulin-Like Growth Factor Binding Protein 1 Expression Inhibits Insulin-Like Growth Factor I Action in MCF-7 Breast Cancer Cells." <u>Cell Growth &amp; Diff.</u> 5:73-77 (1994)                                |
| 171 | Zenobi et al., "Effects of Insulin-Like Growth Factor-I on Glucose Tolerance, Insulin Levels, and Insulin Secretion." <u>J. Clin. Invest.</u> 89:1908-1913 (1992)   |
| 172 | Zenobi et al., "Insulin-Like Growth Factor-I Improves Glucose and Lipid Metabolism in Type 2 Diabetes Mellitus." <u>J. Clin. Invest.</u> 90:2234-2241 (1992)  |
| 173 | Zeslawski et al., "The Interaction of Insulin-Like Growth Factor-I with the N-Terminal Domain of IGFBP-5." <u>EMBO Journal</u> . 20(14):3638-3644 (2001)  |

Examiner

Date Considered

\*Examiner: Initial if reference considered, whether or not citation is in conformance with MPEP 609; draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.